 In this study, researchers examined the effect of two Janus kinase, JAK, inhibitors, Tofacetinob and Ruxalitib, on the generation of cytokine-activated T, TCK, cells and the production of cytokines and chemokines induced by TCK cell macrophage interactions. The results showed that JAK inhibition disrupted T cell-induced macrophage activation and reduced downstream pro-inflammatory cytokine and chemokine responses, suggesting that suppressing the T cell macrophage interaction contributes to the therapeutic effect of JAK inhibitors. This article was authored by Ian B. McKinnis, Duncan Porter, Stefan Siebold, and others.